Trial ID or NCT#

NCT01011478

Status

not recruiting iconNOT RECRUITING

Purpose

RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether rosuvastatin is more effective than a placebo in treating colon cancer that was removed by surgery. PURPOSE: This randomized phase III trial is studying rosuvastatin to see how well it works compared with placebo in treating patients with stage I or stage II colon cancer that was removed by surgery.

Official Title

Statin Polyp Prevention Trial in Patients With Resected Colon Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Irene Wapnir, MD
Irene Wapnir, MD
Surgical oncologist, Breast surgeon, Breast specialist
Professor of Surgery (General Surgery) at the Stanford University Medical Center
Uri Ladabaum
Uri Ladabaum
Gastroenterologist, Geneticist, Cancer geneticist, General gastroenterologist
Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University School of Medicine
Andrew A. Shelton, MD, FACS, FACRS
Andrew A. Shelton, MD, FACS, FACRS
Colorectal surgeon
Clinical Professor, Surgery - General Surgery

Contact us to find out if this trial is right for you.

CONTACT

Cancer Clinical Trials Office
(650) 498-7061